Access to Treatment of Hepatitis C in Prison Inmates

Strock, Paul; Mossong, Joël; Hawotte, K; Arendt, Vic

doi:10.1007/s10620-008-0483-8

Cited by 17 publications

(25 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Incarceration can provide a point of access for HIV/HCV services [16–20], but this does not always translate to successful navigation of the care continuum [21–25]. Community supervision can provide another opportunity to facilitate access to HIV/HCV services, but this opportunity is often not realized [26, 27].…”

Section: Introductionmentioning

confidence: 99%

Associations of criminal justice and substance use treatment involvement with HIV/HCV testing and the HIV treatment cascade among people who use drugs in Oakland, California

Lambdin

Kral

Comfort

et al. 2017

Addict Sci Clin Pract

View full text Add to dashboard Cite

BackgroundPeople who smoke crack cocaine and people who inject drugs are at-risk for criminal justice involvement as well as HIV and HCV infection. Compared to criminal justice involvement, substance use treatment (SUT) can be cost-effective in reducing drug use and its associated health and social costs. We conducted a cross-sectional study of people who smoke crack cocaine and people who inject drugs to examine the association between incarceration, community supervision and substance use treatment with HIV/HCV testing, components of the HIV treatment cascade, social and physical vulnerability and risk behavior.MethodsTargeted sampling methods were used to recruit people who smoke crack cocaine and people who inject drugs (N = 2072) in Oakland, California from 2011 to 2013. Poisson regression models were used to estimate adjusted prevalence ratios between study exposures and outcomes.ResultsThe overall HIV prevalence was 3.3% (95% CI 2.6–4.1). People previously experiencing incarceration were 21% (p < 0.001) and 32% (p = 0.001), respectively, more likely to report HIV and HCV testing; and were not more likely to report receiving HIV care or initiating ART. People previously experiencing community supervision were 17% (p = 0.001) and 15% (p = 0.009), respectively, more likely to report HIV and HCV testing; and were not more likely to report receiving HIV care or initiating ART. People with a history of SUT were 15% (p < 0.001) and 23% (p < 0.001), respectively, more likely to report receiving HIV and HCV testing, 67% (p = 0.016) more likely to report HIV care, and 92% (p = 0.012) more likely to report HIV treatment initiation. People previously experiencing incarceration or community supervision were also more likely to report homelessness, trouble meeting basic needs and risk behavior.ConclusionsPeople with a history of substance use treatment reported higher levels of HCV and HIV testing and greater access to HIV care and treatment among HIV-positive individuals. People with a history of incarceration or community supervision reported higher levels of HCV and HIV testing, but not greater access to HIV care or treatment among HIV-positive individuals., Substance use treatment programs that are integrated with other services for HIV and HCV will be critical to simultaneously address the underlying reasons drug-involved people engage in drug-related offenses and improve access to essential medical services.

show abstract

Section: Introductionmentioning

confidence: 99%

Associations of criminal justice and substance use treatment involvement with HIV/HCV testing and the HIV treatment cascade among people who use drugs in Oakland, California

Lambdin

Kral

Comfort

et al. 2017

Addict Sci Clin Pract

View full text Add to dashboard Cite

show abstract

“…No comparison was made with the nonincarcerated population. Strock et al published a series of 268 prisoners that were known to be HCV positive 14. Treatment with Peg‐IFN‐α and RBV was offered to 86 patients and 52% achieved an SVR.…”

mentioning

confidence: 99%

Comparison of hepatitis C virus treatment between incarcerated and community patients

et al. 2012

View full text Add to dashboard Cite

The prevalence of chronic hepatitis C virus (HCV) infection among incarcerated individuals in the United States is estimated to be between 12-31%. HCV treatment during incarceration is an attractive option due to improved access to healthcare and directly observed therapy. We compared incarcerated and non-incarcerated HCV-infected patients evaluated for treatment at a single academic center between January 1, 2002 and December 31, 2007. During this period, 521 non-incarcerated and 388 incarcerated patients were evaluated for HCV treatment. 319 (61.2%) non-incarcerated patients and 234 (60.3%) incarcerated patients underwent treatment with pegylated interferon and ribavirin. Incarcerated patients were more likely to be male, African-American race, and have a history of alcohol or intravenous drug use. Treated incarcerated patients were less likely to have genotype 1 virus and were less likely to have undergone previous treatment. There was a similar prevalence of co-infection with HIV in both groups. A sustained viral response (SVR) was achieved in 97 (42.9%) incarcerated patients compared to 115 (38.0%) non-incarcerated patients (p=0.304). Both groups had a similar proportion of patients that completed a full treatment course. Stepwise logistic regression was conducted and the final model included full treatment course, non-genotype 1 virus, younger age at treatment start, and negative HIV status. Incarceration status was not a significant predictor when added to this model (p = 0.075). Conclusion In a cohort of HCV-infected patients managed in an academic medical center ambulatory clinic, incarcerated patients were as likely to be treated for HCV and as likely to achieve an SVR as non-incarcerated patients.

show abstract

“…Factors reported as potential obstacles to treatment of chronic HCV infection, especially in correctional populations [5,8,10], such as active drug substance abuse, psychiatric illness, length of treatment and poor adherence did not affect the end points of this study.…”

Section: Resultsmentioning

confidence: 84%

“…Studies in various correctional facilities have suggested that 59 to 85% of patients presenting with confirmed HCV infection go untreated; [8,10,12,13]. Recently Rice has reported a lower proportion (40%) of untreated patients [9].…”

Section: Resultsmentioning

confidence: 99%

“…Despite the relatively high success rates reported in the U.S. and Canada correctional population [4-9], several factors reported as potential obstacles to treatment of chronic HCV infection in the general population, such as active drug substance abuse, psychiatric illness, length of treatment, risk of re-infection, poor adherence and low success rates, may be more prevalent in this setting [5,8,10]. …”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

HCV infected prisoners: should they be still considered a difficult to treat population?

Iacomi¹,

Iannicelli²,

Franceschini³

et al. 2013

BMC Infect Dis

View full text Add to dashboard Cite

BackgroundThe prevalence of chronic hepatitis C virus (HCV) infection in the Italian correctional population is estimated to be around 38%. In this setting HCV infection treatment is controversial because of several factors such as active drug substance abuse, psychiatric illness, length of treatment, risk of re-infection, poor adherence and low success rate.MethodsA retrospective data review of 159 inmates, positive for anti-Hepatitis C virus (HCV) antibody, evaluated to National Institute for Infectious Diseases “L. Spallanzani” (INMI) from January 2006 to December 2009, was conducted to evaluate rate of completion (feasibility) and outcome efficacy of chronic Hepatitis C Virus (HCV) infection treatment with Pegylated Interferon and Ribavirin in five correctional facilities in Rome.ResultsOf the 159 inmates evaluated in the study period, 50, all male (median age 39 years) were treated. Twenty patients (40%) did not complete treatment: 15 showed no response and therapy was stopped, 5 patients (10%) interrupted treatment because of adverse reactions. The global feasibility was 60%. The overall sustained virologic response (SVR) was 50% (32% for genotype 1 and 68% for genotype other than 1). The main predictors of SVR at the Multivariable Logistic Regression Odds Ratio (MLR-OR) were a better pretreatment histological diagnosis (absence of bridging fibrosis or cirrhosis [MLR-OR 11.85; 95% CI 1.96-71.62) and a HCV genotype other than 1 (MLR-OR 5.87; 95% CI 1.49-23.17).ConclusionsChronic HCV infection treatment in correctional facilities is feasible and effective and should be strongly recommended, in combination with preventive measures, in appropriately screened patients because it represents an important opportunity to treat a population with a high prevalence of chronic HCV infection among whom treatment options post incarceration may be limited.

show abstract

Access to Treatment of Hepatitis C in Prison Inmates

Cited by 17 publications

References 23 publications

Associations of criminal justice and substance use treatment involvement with HIV/HCV testing and the HIV treatment cascade among people who use drugs in Oakland, California

Associations of criminal justice and substance use treatment involvement with HIV/HCV testing and the HIV treatment cascade among people who use drugs in Oakland, California

Comparison of hepatitis C virus treatment between incarcerated and community patients

HCV infected prisoners: should they be still considered a difficult to treat population?

Contact Info

Product

Resources

About